Sweden's Newbury Pharmaceuticals Q4 revenue more than doubles on new product launches 

Overview

• Sweden specialty drug maker's Q4 net revenue grew about 130% yr/yr on new launches

• Q4 EBITDA loss narrowed compared to last year

• Company secured new generic approvals and exclusive rights to hospital portfolio in Iraq

Outlook

• Company expects gross margin to improve in coming quarters

• Company prioritizes reaching EBITDA breakeven as foundation for long-term growth

• Company remains on track to launch over 30 products in Nordics by Dec 2026

Result Drivers

• NEW PRODUCT LAUNCHES - Co said Q4 revenue growth was driven by additional product launches and increased participation in tenders across the Nordics

• MARGIN PRESSURE - Co said gross margin declined due to product mix and price pressure in tenders, limiting earnings improvement despite higher revenue

• SLOW INTERNATIONAL SALES - Co said international sales were limited as activities in the Middle East progressed slower than expected due to geopolitical factors

Company press release:

Key Details

Analyst Coverage

• The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago

Reuters Recommended Reads

• Oct 27 - Novartis slightly misses Q3 net sales estimates, but tops core EPS view

• Oct 27 - Pharming Group Q3 revenue rises on US demand; tightens guidance

• Oct 26 - Acumen Pharmaceuticals posts smaller than expected Q3 loss

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)